论文部分内容阅读
急性冠脉综合征会出现急性心肌缺血、心功能受损和心律失常,进而导致急性心力衰竭的发生.而急性心力衰竭又反过来使得急性冠脉综合征的病情变得更加复杂,在治疗过程中,往往需要正性肌力药物来控制病情.而传统的正性肌力药物会增加心肌耗氧量,反而增加患者死亡率.近几年来,左西孟旦作为一种不增加心肌耗氧的钙增敏剂应运而生.根据许多研究,它已被认为适合用于急性冠脉综合征导致的急性心力衰竭患者中.并逐渐发现,左西孟旦除了“钙增敏”作用之外,还有其他的有助于病情改善的作用.现综述目前为止关于左西孟旦在急性冠脉综合征合并急性心力衰竭中作用机制和疗效评价的研究报道,旨在能更加全面地认识该药物在急性冠脉综合征合并急性心力衰竭中的作用并为进一步挖掘其潜能提供思路.“,”Acute coronary syndrome(ACS)can cause acute myocardial ischemia,impairment of heart function,and arrhythmia,which lead to acute heart failure(AHF).AHF,in turn,makes the condition of ACS more complicated.The positive inotropic drugs are often needed to control the illness during the process of treatment.The traditional inotropic agents will increase myocardial oxygen consumption,and improve the mortality.Levosimendan,as a calcium sensitizer,which is a inotropic effect that does not increase myocardial oxygen consumption,came into being in recent years.According to many studies,it has been thought to be suitable for patients with AHF caused by ACS.Nowadays,people have gradually found that in addition to“calcium sensitization”of levosimendan,there are other factors that help to improve the condition.This review summarizes the reports so far on the mechanism and efficacy of levosimendan in the treatment of ACS complicated with AHF,so that people can fully understand the role of levosimendan in ACS complicated with AHF and provide ideas for further exploring of its potential.